Glenmark开始抗病毒药物Favipiravir的3期试验,以检查其对印度COVID-19患者的疗效

Glenmark开始抗病毒药物Favipiravir的3期试验,以检查其对印度COVID-19患者的疗效

Glenmark Pharmaceuticals周二表示

该公司已启动抗病毒药物Favipiravir的3期临床试验,以检查其对印度COVID-19患者的疗效。

孟买公司

上个月已获得印度药品总局(DCGI)的批准,可进行Favipiravir抗病毒片剂治疗COVID-19患者的临床试验。

Glenmark Pharmaceuticals

is the first company in the country to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India, it said in a statement.

Glenmark begins Phase 3 trials of antiviral drug Favipiravir to check efficacy on COVID-19 patients in India

Favipiravir is a generic version of Japan-based Fujifilm Toyama Chemical’s Avigan. Image credit: Reuters

Clinical trials

have commenced and over ten leading government and private hospitals are being enrolled for the study, it added.

Glenmark estimates study completion by July-August 2020, it said.

As per the approved clinical trial protocol,

150 subjects with mild to moderate COVID-19 symptoms will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care.

Treatment duration is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.

Several health and medical experts, both in and outside of Glenmark are eager to see the effect that Favipiravir has on COVID-19 cases.

We believe the study results will be significant as there is currently no effective treatment for the virus,” Glenmark Pharmaceuticals Vice President & Head Clinical Development, Global Specialty/Branded Portfolio Monika Tandon said.

The data we get from these trials will point us in a clearer direction with regard to COVID-19 treatment and management, she added.

Firstpost

https://www.firstpost.com/health/glenmark-begins-phase-3-trials-of-antiviral-drug-favipiravir-to-check-efficacy-on-covid-19-patients-in-india-8358671.html/amp